Skip to content

Return on assets at other companies

Pfizer logo
PfizerPFE
4.6%
Amgen logo
AmgenAMGN
8.6%+2.1pp
Incyte logo
IncyteINCY
21.9%+21.5pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-45.4%-1,198pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-34.3%+2.7pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-24.3%-2.2pp

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.42B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed October 28, 2025, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s return on assets?
Arcutis Biotherapeutics, Inc. (ARQT) reported return on assets of -11% in Q3 2025.
How has Arcutis Biotherapeutics, Inc.'s return on assets changed year-over-year?
Arcutis Biotherapeutics, Inc.'s return on assets increased by 79.5% year-over-year, from -53.5% to -11%.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s return on assets?
Over 4 years (2020 to 2024), Arcutis Biotherapeutics, Inc.'s return on assets has grown at a -11.8% compound annual growth rate (CAGR), from -67% to -40.6%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.